Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAHMSV)

• Drug Name: Fucose Drug Info
• Synonyms: L-galactomethylose; 6-Desoxygalactose; SCHEMBL13092958; AKOS030212707
• Cross-matching ID:
  PubChem CID: 17106
  ChEBI ID: CHEBI:2181
  CAS Number: CAS 87-96-7
  TTD Drug ID: DMAHMSV
  VARIDT Drug ID: DR00198

Molecule-Related Drug Atlas

Drug(s) Targeting P-selectin (SELP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizanlizumab	DMAHOVJ	Vaso-occlusive crisis	BE2Y	Approved	[3]
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[4]
Inclacumab	DMXV94M	Sickle-cell disorder	3A51	Phase 3	[5]
CY-1503	DML906E	Hypertension	BA00-BA04	Phase 2/3	[6]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[7]
SelG1	DMTQ2K0	Vaso-occlusive crisis	BE2Y	Phase 2	[8]
RPSGL-Ig	DM0BFJ5	Delayed graft function	4B24.0	Phase 2	[9]
PSI-697	DM75FWO	Atherosclerosis	BD40	Phase 1	[10]
CDP-850	DMWHQM3	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[11]
CY-1787	DMWY2NT	Allergy	4A80-4A85	Discontinued in Phase 1	[12]

Drug(s) Targeting Cytotoxic T-lymphocyte protein 4 (CTLA-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ipilimumab	DMJTIYK	Melanoma	2C30	Approved	[13]
Tremelimumab	DMOQ9H1	Hepatocellular carcinoma	2C12.02	Approved	[14]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[15]
AK04	DMU7K86	Actinic keratosis	EK90.0	Phase 3	[16]
AK104	DMXJ8Z4	Cervical cancer	2C77.0	Phase 2	[17]
Lorigerlimab	DM2E8Z5	Prostate cancer	2C82.0	Phase 2	[18]
Vudalimab	DMSEEI0	Prostate cancer	2C82.0	Phase 2	[19]
AGEN1884	DMAP5B4	Cervical cancer	2C77.0	Phase 1/2	[20]
BMS-986288	DMM10J4	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[21]
MK-1308	DM25QKC	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[22]

Drug(s) Targeting Urokinase-type plasminogen activator (PLAU)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pro-urokinase	DMGKT2L	Thrombin deficiency	3B14.Z	Approved	[23]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[24]
PAI-1	DMY2AEF	N. A.	N. A.	Phase 4	[25]
Amediplase	DM4FPM3	Myocardial infarction	BA41-BA43	Phase 3	[26]
Upamostat	DMFZULI	Breast cancer	2C60-2C65	Phase 2	[27]
Saruplase	DM1M0PR	Thrombosis	DB61-GB90	Phase 2	[28]
HTU-PA	DMNHE43	Cerebrovascular ischaemia	8B1Z	Phase 1/2	[29]
PMID18163548C4	DMHPME3	Myocardial ischemia	BA6Z	Clinical trial	[30]
UK-356202	DMSRK2A	Myocardial hypertrophy	BC45	Clinical trial	[31]
PAI-2	DMRSMW8	N. A.	N. A.	Discontinued in Phase 2	[32]

Drug(s) Targeting Alpha-galactosidase A (GLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pegunigalsidase alfa	DMOUW65	Fabry disease	5C56.01	Approved	[33]
Migalastat	DMFIQ2H	Fabry disease	5C56.01	Approved	[34]
AVR-RD-01	DMC1XHK	Fabry disease	5C56.01	Phase 1/2	[35]
ST-920	DMOJIPG	Fabry disease	5C56.01	Phase 1/2	[36]
4D-310	DMNG59Y	Fabry disease	5C56.01	Phase 1/2	[37]
isaralgagene civaparvovec	DM5SSPZ	Fabry disease	5C56.01	Phase 1/2	[38]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[1]
2,5-dideoxy-2,5-imino-D-altritol	DMI1O54	Discovery agent	N.A.	Investigative	[39]
Beta-1-C-Butyl-1-deoxygalactonojirimycin	DMMKDEZ	Discovery agent	N.A.	Investigative	[39]
Beta-1-C-butenyl-1-deoxygalactonojirimycin	DM6GTBC	Discovery agent	N.A.	Investigative	[39]

Drug(s) Targeting Lactase-phlorizin hydrolase (LCT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[1]
Nojirimycine Tetrazole	DMYZRTB	Discovery agent	N.A.	Investigative	[40]
2,5-dideoxy-2,5-imino-D-altritol	DMI1O54	Discovery agent	N.A.	Investigative	[39]
Gluconolactone	DMO071E	Discovery agent	N.A.	Investigative	[40]
ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE	DM0O4A2	Discovery agent	N.A.	Investigative	[40]
Hyacinthacine B3	DMJ9KNU	Discovery agent	N.A.	Investigative	[41]
D-Gluconhydroximo-1,5-Lactam	DM527XP	Discovery agent	N.A.	Investigative	[40]
2,5-dideoxy-2,5-imino-dl-glycero-D-manno-heptitol	DMKP7O0	Discovery agent	N.A.	Investigative	[42]
2-Deoxy-2fluoro-Glucose	DMMC8IG	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Acetylcholinesterase (AChE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[43]
Donepezil	DMIYG7Z	Advanced cancer	2A00-2F9Z	Approved	[44]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[45]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[46]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[47]
Neostigmine	DM6T2J3	Myasthenia gravis	8C6Y	Approved	[48]
YM443	DMNZCI1	Functional dyspepsia	DD90.3	Approved	[49]
Ambenonium	DMOP0BL	Myasthenia gravis	8C6Y	Approved	[50]
Demecarium bromide	DMAYEU1	Open-angle glaucoma	9C61	Approved	[51]
Isoflurophate	DMBSK7X	Glaucoma/ocular hypertension	9C61	Approved	[52]

Drug(s) Targeting Dipeptidyl peptidase 4 (DPP-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Saxagliptin	DMGXENV	Type-2 diabetes	5A11	Approved	[53]
Sitagliptin	DMGDKXN	Cystic fibrosis	CA25	Approved	[54]
Alogliptin	DM8WI3R	Type-2 diabetes	5A11	Approved	[55]
Linagliptin	DMWFJTR	Non-insulin dependent diabetes	5A11	Approved	[56]
Vildagliptin	DMYN59P	Type-2 diabetes	5A11	Approved	[57]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride	DM34TXO	Type-2 diabetes	5A11	Approved	[24]
Anagliptin	DMJXIC9	Type-2 diabetes	5A11	Approved	[58]
SaxaDapa FDC	DMAPRWV	Diabetic complication	5A2Y	Phase 3	[59]
LC-150444	DM09RKB	Type-2 diabetes	5A11	Phase 3	[60]
Dutogliptin	DMM5VTA	Type-2 diabetes	5A11	Phase 3	[61]

Drug(s) Targeting Influenza Neuraminidase (Influ NA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oseltamivir	DMGO72P	Influenza	1E30-1E32	Approved	[62]
Zanamivir	DMFMBZ4	Influenza	1E30-1E32	Approved	[62]
Peramivir	DMNXY5K	Influenza virus infection	1E30-1E32	Approved	[63]
UX-001	DMD2O0L	Hereditary inclusion body myositis	4A41.2	Phase 3	[1]
CS-8958	DM4CSDH	Influenza virus infection	1E30-1E32	Phase 3	[63]
DAS-181	DM0Y8JP	Influenza virus infection	1E30-1E32	Phase 2	[64]
Lactose	DMO4GPK	Discovery agent	N.A.	Phase 1	[1]
GS-3435	DMV7JC6	Influenza virus infection	1E30-1E32	Terminated	[65]
BCX-140	DMBJERO	Influenza virus infection	1E30-1E32	Terminated	[66]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Neutrophil elastase (NE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sivelestat sodium hydrate	DMOSJD0	Acute lung injury	NB32.3	Phase 4	[67]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[68]
Sivelestat	DM6BZCV	Crohn disease	DD70	Phase 3	[69]
Tiprelestat	DM1SB94	Myocardial infarction	BA41-BA43	Phase 2	[70]
AZD9668	DMB87M3	Bronchiectasis	CA24	Phase 2	[71]
L-694,458	DMA0DSJ	Cystic fibrosis	CA25	Phase 2	[72]
BAY 85-8501	DMCPUKG	Bronchiectasis	CA24	Phase 2	[73]
DX-890	DMBFZET	Acute lung injury	NB32.3	Phase 2	[67]
POL-6014	DM9B68S	Cystic fibrosis	CA25	Phase 1	[74]
AZD-9819	DMWYHXG	Chronic obstructive pulmonary disease	CA22	Phase 1	[75]

Drug(s) Targeting Coagulation factor VII (F7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Factor viia	DMZUW6P	Hemophilia	3B10.0	Approved	[76]
Vatreptacog alfa (activated)	DMANKTO	Bleeding disorder	GA20-GA21	Phase 3	[77]
BAX-817	DMB147A	Hemophilia	3B10.0	Phase 3	[78]
Activated recombinant FVII-albumin fusion protein	DMKY9GI	Hemophilia	3B10.0	Phase 2/3	[79]
Recombinant factor VIIa PEGylated liposomal	DMY3TAD	Factor VII deficiency	3B14	Phase 1/2	[76]
F-7TG	DML4JXZ	Hemophilia	3B10.0	Phase 1	[76]
Eptacog alfa	DMAQYRL	Hemophilia	3B10.0	Phase 1	[80]
CB-813	DMXQGKL	Hemophilia	3B10.0	Phase 1	[81]
BAY 86-6150	DM6R3WC	Hemophilia	3B10.0	Discontinued in Phase 2/3	[82]
RNAPc2	DME9V0I	Colorectal cancer	2B91.Z	Discontinued in Phase 2	[83]

Drug(s) Targeting Insulin-like growth factor I receptor (IGF1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Teprotumumab	DM4L59B	Graves disease	5A02.0	Approved	[84]
Mecasermin	DM1O3BY	Growth failure	LD2F.1Y	Approved	[85]
Somatomedin-1	DMZ9FAO	Hormone deficiency	5A61.1	Approved	[86]
OSI-906	DMHKZLF	Solid tumour/cancer	2A00-2F9Z	Phase 3	[87]
Rinfabate	DML9FD4	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[88]
MM-141	DM2RJ4D	Pancreatic cancer	2C10	Phase 2	[89]
TT-100	DMZE6Y9	Non-small-cell lung cancer	2C25.Y	Phase 2	[90]
AMG 479	DM0DRAZ	Breast cancer	2C60-2C65	Phase 2	[91]
VPI-2690B	DMUQZT4	Diabetic nephropathy	GB61.Z	Phase 2	[92]
AXL-1717	DMTQ1Y3	Solid tumour/cancer	2A00-2F9Z	Phase 2	[93]

Drug(s) Targeting Membrane-associated lectin type-C (CD209)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Lactotransferrin (LTF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Parecoxib	DMIV8CT	N. A.	N. A.	Phase 4	[40]
Talactoferrin	DMV7T64	Diabetic foot ulcer	BD54	Phase 3	[94]
HLF 1-11	DMDFG1O	Bacteremia	1A73	Phase 1/2	[95]
Nimesulide	DMR1NMD	Metastatic colorectal cancer	2B91	Terminated	[96]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[1]
Lauric Acid	DM9C8KQ	Discovery agent	N.A.	Investigative	[1]
Alpha-D-Fucose	DM6VH7A	Discovery agent	N.A.	Investigative	[1]
Nitrilotriacetic Acid	DMIOQFU	Discovery agent	N.A.	Investigative	[1]
3h-Indole-5,6-Diol	DMBFCTZ	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Cathepsin S (CTSS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG7625	DMDGPKS	Autoimmune disease	4A40-4A45	Phase 2	[97]
SAR-114137	DMZ1XR5	Pain	MG30-MG3Z	Phase 1	[98]
VBY- 891	DMTKPH4	Autoimmune diabetes	5A10	Phase 1	[99]
VBY- 036	DMULRYC	Neuropathic pain	8E43.0	Phase 1	[100]
VBY-129	DM4YIWK	Autoimmune diabetes	5A10	Phase 1	[101]
PMID27998201-Compound-12	DM8QZNC	Bone cancer	2B5Z	Patented	[102]
PMID27998201-Compound-5	DMVZ0ND	Chronic obstructive pulmonary disease	CA22	Patented	[102]
PMID27998201-Compound-9	DM1JOZN	Rheumatoid arthritis	FA20	Patented	[102]
PMID25399719-Compound-17	DMRXKJZ	N. A.	N. A.	Patented	[103]
PMID27998201-Compound-17	DMAZVHJ	Hair loss	ED70	Patented	[102]

Drug(s) Targeting E-selectin (SELE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[4]
GMI-1271	DMDTGWQ	Acute myeloid leukaemia	2A60	Phase 3	[104]
CY-1503	DML906E	Hypertension	BA00-BA04	Phase 2/3	[6]
Bimosiamose	DM0TH9A	Atopic dermatitis	EA80	Phase 2a	[105]
GMI-1359	DML1KSA	Breast cancer	2C60-2C65	Phase 1	[106]
PF-07209326	DM7YRAL	Sickle-cell disorder	3A51	Phase 1	[107]
GI-270384X	DM3KN2Q	Inflammatory bowel disease	DD72	Terminated	[108]
O-Sialic Acid	DMCAR7B	Discovery agent	N.A.	Investigative	[40]
Efomycine M	DMOKX76	Discovery agent	N.A.	Investigative	[109]
1na	DM0A1YI	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Complement C1s component (C1S)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cinryze	DMVIKJZ	Hereditary angioedema	4A00.14	Approved	[110]
Sutimlimab	DMY7WH1	Cold type autoimmune haemolytic anemia	3A20.1	Approved	[111]
SAR445088	DMQV3IM	Chronic inflammatory demyelinating polyneuropathy	8C01.3	Phase 2	[112]
TS01	DMNTVUK	Stroke	8B20	Phase 1	[113]
SHP616	DMO0CA8	Neuromyelitis optica	8A43	Phase 1	[97]
ANX005	DMAESIY	Neurodegenerative disorder	8A20-8A23	Phase 1	[114]
TNT009	DMSKF29	Bullous pemphigoid	EB41.0	Phase 1	[97]
PMID16460935C28	DM8BKI4	Discovery agent	N.A.	Investigative	[115]

Drug(s) Targeting Immunoglobulin epsilon Fc receptor gamma (FCERG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Omalizumab	DMETVFJ	Asthma	CA23	Approved	[116]
Benzylpenicilloyl Polylysine	DMQHM2D	Bacterial infection	1A00-1C4Z	Approved	[117]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Cholinesterase (BCHE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hexafluronium bromide	DMFY307	Spasm	MB47.3	Approved	[118]
MEPTAZINOL	DMPSB8F	Pain	MG30-MG3Z	Approved	[119]
Eptastigmine	DMTV7ZM	Cognitive impairment	6D71	Phase 3	[120]
(-)-Phenserine	DMNCY1I	Alzheimer disease	8A20	Phase 3	[121]
Plasma derived human butyrylcholinesterase	DMF3IBC	Neurotoxicity	NE61	Phase 1	[122]
Protexia	DME1Y9W	Alzheimer disease	8A20	Phase 1	[123]
JES-9501	DMYR3IE	Alzheimer disease	8A20	Phase 1	[124]
Tetra-hydro-isoquinoline derivative 3	DMCZA45	N. A.	N. A.	Patented	[125]
Tetra-hydro-isoquinoline derivative 1	DML86IO	N. A.	N. A.	Patented	[125]
Tetra-hydro-isoquinoline derivative 2	DM5CKVF	N. A.	N. A.	Patented	[125]

Drug(s) Transported By Sodium/glucose cotransporter 1 (SLC5A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[2]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Inhibitor	[1]
Alpha-galactosidase A (GLA)	TTIS03D	AGAL_HUMAN	Inhibitor	[1]
Cathepsin S (CTSS)	TTUMQVO	CATS_HUMAN	Inhibitor	[1]
Cholinesterase (BCHE)	TTEB0GD	CHLE_HUMAN	Inhibitor	[1]
Coagulation factor VII (F7)	TTF0EGX	FA7_HUMAN	Inhibitor	[1]
Complement C1s component (C1S)	TT7LRQH	C1S_HUMAN	Inhibitor	[1]
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	TTI2S1D	CTLA4_HUMAN	Inhibitor	[1]
Dipeptidyl peptidase 4 (DPP-4)	TTDIGC1	DPP4_HUMAN	Inhibitor	[1]
E-selectin (SELE)	TTAU4D6	LYAM2_HUMAN	Inhibitor	[1]
Immunoglobulin epsilon Fc receptor gamma (FCERG)	TTDGEC0	FCERG_HUMAN	Inhibitor	[1]
Influenza Neuraminidase (Influ NA)	TT50QJ3	NRAM_I33A0	Inhibitor	[1]
Insulin-like growth factor I receptor (IGF1R)	TTHRID2	IGF1R_HUMAN	Inhibitor	[1]
Lactase-phlorizin hydrolase (LCT)	TTA0OSE	LPH_HUMAN	Inhibitor	[1]
Lactotransferrin (LTF)	TTSZDQU	TRFL_HUMAN	Inhibitor	[1]
Membrane-associated lectin type-C (CD209)	TTBXIM9	CD209_HUMAN	Inhibitor	[1]
Neutrophil elastase (NE)	TTPLTSQ	ELNE_HUMAN	Inhibitor	[1]
P-selectin (SELP)	TTE5VG0	LYAM3_HUMAN	Inhibitor	[1]
Urokinase-type plasminogen activator (PLAU)	TTGY7WI	UROK_HUMAN	Inhibitor	[1]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Sodium/glucose cotransporter 1 (SLC5A1)	DTOKC04	SC5A1_HUMAN	Substrate	[2]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS One. 2014 Feb 26;9(2):e89977.
• [3] Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.
• [4] Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
• [5] Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics. Expert Opin Biol Ther. 2022 Nov;22(11):1417-1428.
• [6] Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
• [7] Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
• [8] Clinical pipeline report, company report or official report of Selexys Pharmaceuticals (2011).
• [9] rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6.
• [10] Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007.
• [11] WO patent application no. 2001,0276,21, Competitive inhibition elisa for antibody detection.
• [12] Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med. 1996 Feb;24(2):229-33.
• [13] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
• [15] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [16] A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.
• [17] Clinical pipeline report, company report or official report of Akeso Biopharma.
• [18] Clinical pipeline report, company report or official report of MacroGenics
• [19] Clinical pipeline report, company report or official report of Xencor
• [20] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [21] Clinical pipeline report, company report or official report of CytomX Therapeutics.
• [22] Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
• [24] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [25] Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6.
• [26] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [27] Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70.
• [28] Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost. 1994 Nov;72(5):740-4.
• [29] Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986 Mar 25;261(9):4352-7.
• [30] Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem. 2008 Jan 24;51(2):183-6.
• [31] Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.
• [32] Topological localization of plasminogen activator inhibitor type 2. Cytometry. 2000 May 1;40(1):32-41.
• [33] Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015 Feb;114(2):259-67.
• [34] AT-1001: a high-affinity alpha3beta4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol. 2015 Apr;172(7):1834-45.
• [35] Clinical pipeline report, company report or official report of Avrobio.
• [36] AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction. Mol Ther Methods Clin Dev. 2020 Jul 9;18:607-619.
• [37] Clinical pipeline report, company report or official report of 4D Molecular Therapeutics
• [38] ClinicalTrials.gov (NCT04046224) A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR). U.S.National Institutes of Health.
• [39] 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4.
• [40] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [41] New polyhydroxylated pyrrolidine, piperidine, and pyrrolizidine alkaloids from Scilla sibirica. J Nat Prod. 2002 Dec;65(12):1875-81.
• [42] Nitrogen-containing furanose and pyranose analogues from Hyacinthus orientalis. J Nat Prod. 1998 May;61(5):625-8.
• [43] Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
• [44] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
• [45] Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
• [46] [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
• [47] Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
• [48] Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
• [49] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [50] Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
• [51] The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
• [52] Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
• [53] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [54] Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
• [55] Clinical pipeline report, company report or official report of Takeda (2009).
• [56] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [57] Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
• [58] Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
• [59] Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
• [60] Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
• [61] Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.
• [62] Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102.
• [63] Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13.
• [64] Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009 Nov 6;4(11):e7838.
• [65] US patent application no. 2010,0081,713, Compositions and methods for treating viral infections.
• [66] CN patent application no. 104447481, Benzoic acid thiourea anti-influenza virus compounds as well as preparation method and use thereof.
• [67] Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77.
• [68] Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. Bioorg Med Chem Lett. 2010 Jan 15;20(2):513-5.
• [69] Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203.
• [70] Company report (Proteo Biotech AG)
• [71] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [72] Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
• [73] Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 5-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem. 2015 Jul;10(7):1163-73.
• [74] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358).
• [75] Lipid Peroxide-Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples. Drug Metab Dispos. 2015 Oct;43(10):1441-9.
• [76] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363).
• [77] Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9.
• [78] Clinical pipeline report, company report or official report of Baxter.
• [79] ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.
• [80] Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. BioDrugs. 2008;22(2):121-36.
• [81] Clinical pipeline report, company report or official report of Catalyst Biosciences.
• [82] Bayer HealthCare and Maxygen Announce Hematology Agreement. U.S. Securities and Exchange Commission. July 2, 2008.
• [83] rNAPc2 inhibits colorectal cancer in mice through tissue factor. Clin Cancer Res. 2009 Jan 1;15(1):208-16.
• [84] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [85] IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45.
• [86] 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
• [87] Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family... Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5.
• [88] Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D. 2005;6(2):120-7.
• [89] MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
• [90] BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
• [91] Clinical pipeline report, company report or official report of Amgen (2009).
• [92] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [93] Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7.
• [94] Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. Am J Surg. 2007 Jan;193(1):49-54.
• [95] The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004 Dec;48(12):4919-21.
• [96] Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
• [97] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [98] From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
• [99] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
• [100] Clinical pipeline report, company report or official report of ViroBay.
• [101] Clinical pipeline report, company report or official report of ViroBay.
• [102] Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
• [103] An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
• [104] Clinical pipeline report, company report or official report of glycomimetics.
• [105] Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia. Shock. 2008 Apr;29(4):475-82.
• [106] Clinical pipeline report, company report or official report of GlycoMimetics.
• [107] ClinicalTrials.gov (NCT04255875) A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED EVALUATION OF SINGLE DOSES OF PF-07209326 IN HEALTHY PARTICIPANTS (SAFETY, TOLERABILITY, AND PHARMACOKINETICS [PK]) FOLLOWED BY AN OPEN LABEL, REPEAT DOSE EVALUATION IN SICKLE CELL DISEASE PARTICIPANTS (SAFETY, TOLERABILITY, PK AND EFFICACY). U.S.National Institutes of Health.
• [108] Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96.
• [109] Interfering with leukocyte rolling--a promising therapeutic approach in inflammatory skin disorders Trends Pharmacol Sci. 2003 Feb;24(2):49-52.
• [110] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [111] Antibodies to watch in 2020. MAbs. Jan-Dec 2020;12(1):1703531.
• [112] First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor. Clin Transl Sci. 2023 Apr;16(4):673-685.
• [113] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [114] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [115] A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2200-4.
• [116] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [117] Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin. Arch Dis Child. 1980 Nov;55(11):857-60.
• [118] Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90.
• [119] Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
• [120] Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85.
• [121] Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93.
• [122] Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life. Bioconjug Chem. 2015 Aug 19;26(8):1753-8.
• [123] In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005 Dec 15;157-158:363-5.
• [124] Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5.
• [125] A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.